Genaera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics
Genaera Corporation (Nasdaq: GENR) announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin pathways through the highly selective inhibition of its novel target enzyme, PTP-1B.
Medical News Today – Dec 2, 2008 08:00 AM [GMT]
found in Health: Diabetes
Genaera Corporation (Nasdaq: GENR) announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin pathways through the highly selective inhibition of its novel target enzyme, PTP-1B.
Medical News Today – Dec 2, 2008 08:00 AM [GMT]
found in Health: Diabetes
0 comments
Profanity Filter Is OffNo comments have been posted to this article.
Add Your Comments
Become a news-spider.com member to comment on this article. It's free to join and only takes a minute. Once you're a member you can comment on articles, create a custom profile, customize your settings, build a friends network, and more.
Already a member? Sign In to add your comments.